Dexamethasone-induced modulation of the BIM locus. (A) Schematic demonstrating the primers used in the ChIP study covering the BIM promoter and first intron. (B-C) RNA Pol II binding and (D-E) histone acetylation at the BIM locus were determined in (B,D) ALL-50 and (C,E) ALL-54 following 8-hour treatment with dexamethasone or vehicle control in vivo. The data for each point were generated with samples from 3 randomized ALL-engrafted mice. (F) Schematic showing GR binding at the BIM IGR (intronic GR binding region) from the ChIP-seq data. Four pairs of primers were designed to cover 5 to 10 kb up- and downstream of the BIM IGR region. (G) GR binding at the BIM IGR in ALL-50 and ALL-54 following treatment with dexamethasone or vehicle control in vivo (n = 3). (H) Time course study of GR binding at the BIM IGR in ALL-54 following dexamethasone treatment in vitro (n = 3). (I) Regression curve of dexamethasone-induced fold changes of BIM expression vs enrichment of GR binding at the BIM IGR in 11 xenografts, P = .03. BIM expression was detected by RT-PCR using 3 independent experiments in vitro. (J) RNA Pol II binding at the BIM IGR as well as up- and downstream regions in ALL-54 following 8-hour treatment with dexamethasone or vehicle control in vivo (n = 3). TSS, transcription start site; Dex, dexamethasone. *P < .05.